Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

373 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Caliò A, Cuppone F, Sperduti I, Giannarelli D, Chilosi M, Bronte V, Scarpa A, Bria E, Tortora G. Carbognin L, et al. Among authors: chilosi m. PLoS One. 2015 Jun 18;10(6):e0130142. doi: 10.1371/journal.pone.0130142. eCollection 2015. PLoS One. 2015. PMID: 26086854 Free PMC article.
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors.
Pilotto S, Sperduti I, Novello S, Peretti U, Milella M, Facciolo F, Vari S, Leuzzi G, Vavalà T, Marchetti A, Mucilli F, Crinò L, Puma F, Kinspergher S, Santo A, Carbognin L, Brunelli M, Chilosi M, Scarpa A, Tortora G, Bria E. Pilotto S, et al. Among authors: chilosi m. J Thorac Oncol. 2015 Sep;10(9):1341-1348. doi: 10.1097/JTO.0000000000000628. J Thorac Oncol. 2015. PMID: 26200453 Free article.
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis.
Massari F, Ciccarese C, Caliò A, Munari E, Cima L, Porcaro AB, Novella G, Artibani W, Sava T, Eccher A, Ghimenton C, Bertoldo F, Scarpa A, Sperandio N, Porta C, Bronte V, Chilosi M, Bogina G, Zamboni G, Tortora G, Samaratunga H, Martignoni G, Brunelli M. Massari F, et al. Among authors: chilosi m. Target Oncol. 2016 Jun;11(3):345-51. doi: 10.1007/s11523-015-0396-3. Target Oncol. 2016. PMID: 26566945
True 3q chromosomal amplification in squamous cell lung carcinoma by FISH and aCGH molecular analysis: impact on targeted drugs.
Brunelli M, Bria E, Nottegar A, Cingarlini S, Simionato F, Caliò A, Eccher A, Parolini C, Iannucci A, Gilioli E, Pedron S, Massari F, Tortora G, Borze I, Knuutila S, Gobbo S, Santo A, Tondulli L, Calabrò F, Martignoni G, Chilosi M. Brunelli M, et al. Among authors: chilosi m. PLoS One. 2012;7(12):e49689. doi: 10.1371/journal.pone.0049689. Epub 2012 Dec 6. PLoS One. 2012. PMID: 23236352 Free PMC article.
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma.
Brunello E, Bogina G, Bria E, Vergine M, Zamboni G, Pedron S, Daniele I, Furlanetto J, Carbognin L, Marconi M, Manfrin E, Ibrahim M, Miller K, Tortora G, Molino A, Jasani B, Beccari S, Bonetti F, Chilosi M, Martignoni G, Brunelli M. Brunello E, et al. Among authors: chilosi m. J Cancer Res Clin Oncol. 2013 Sep;139(9):1563-8. doi: 10.1007/s00432-013-1479-0. Epub 2013 Jul 28. J Cancer Res Clin Oncol. 2013. PMID: 23892410
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.
Bria E, Pilotto S, Amato E, Fassan M, Novello S, Peretti U, Vavalà T, Kinspergher S, Righi L, Santo A, Brunelli M, Corbo V, Giglioli E, Sperduti I, Milella M, Chilosi M, Scarpa A, Tortora G. Bria E, et al. Among authors: chilosi m. Oncotarget. 2015 May 20;6(14):12783-95. doi: 10.18632/oncotarget.3727. Oncotarget. 2015. PMID: 25904052 Free PMC article.
373 results